国产av精选一区二区三区_午夜久久精品三级毛片_黄色三级毛片在线视频_邻居老头把我弄舒服死了_亚洲国产五月综合网_国产a∨精品成人网址_玖玖午夜福利视频_天堂√中文最新版在线_日韩欧美另类综合一区_亚洲欧美日韩性爱一区精品

?

Bio-Thera's Recombinant Humanized anti-HER2 Monoclonal Antibody-Maytansine Conjugates for Injection's Approved for Clinical Trials in China

Date: 2016-10-20Click:

Recently, the Antibody-Drug Conjugates (ADCs) program’s ‘Recombinant Humanized anti-HER2 Monoclonal Antibody-Maytansine Conjugates for Injection’ (BAT8001) was approved for clinical trials in China. BAT8001 is suitable for multiple cancer disease indications, including HER2 over-expressed metastatic breast cancer as well as metastatic gastric cancer. Bio-Thera is proud that BAT8001 represents a class of novel drugs and also is the independent intellectual property developed by Bio-Thera. Thus far, we have patented the compound and preparation method of this drug and have respectively obtained three patent licenses from the Chinese Patent Office and four patent licenses from the US Patent Office.